Use of relative and absolute effect measures in reporting health inequalities: Structured review

BMJ (Online)

Volumn 345, Issue 7878, 2012, Pages

  King, Nicholas B ^a   Harper, Sam ^b   Young, Meredith E ^b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL PRACTICE; DATA ANALYSIS; DECISION MAKING; HEALTH DISPARITY; HUMAN; MEDICAL LITERATURE; MEDICAL RESEARCH; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SOCIAL STATUS; EPIDEMIOLOGY; STATISTICAL ANALYSIS;

DATA INTERPRETATION, STATISTICAL; EPIDEMIOLOGIC METHODS; HEALTH STATUS DISPARITIES; HUMANS;

EID: 84867411377     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.e5774     Document Type: Review

References (39)

1. Barratt A, Wyer PC, Hatala R, McGinn T, Dans AL, Keitz S, et al. Tips for learners of evidence-based medicine: 1. Relative risk reduction, absolute risk reduction and number needed to treat. CMAJ 2004;171:353-8. (Pubitemid 39127990)
2. Forrow L, Taylor WC, Arnold RM. Absolutely relative: how research results are summarized can affect treatment decisions. Am J Med 1992;92:121-4.
3. Naylor CD, Chen E, Strauss B. Measured enthusiasm: does the method of reporting trial results alter perceptions of therapeutic effectiveness? Ann Intern Med 1992;117:916-21.
4. Malenka DJ, Baron JA, Johansen S, Wahrenberger JW, Ross JM. The framing effect of relative and absolute risk. J Gen Intern Med 1993;8:543-8. (Pubitemid 23312931)
5. Freedman B, Shapiro SH. Ethics and statistics in clinical research - towards a more comprehensive examination. J Stat Plan Inference 1994;42:223-40.
6. Schechtman E. Odds ratio, relative risk, absolute risk reduction, and the number needed to treat - which of these should we use? Value Health 2002;5:431-6.
7. Fries JF, Krishnan E. Equipoise, design bias, and randomized controlled trials: the elusive ethics of new drug development. Arthritis Res Ther 2004;6:R250-5.
8. Slowther A, Ford S, Schofield T. Ethics of evidence based medicine in the primary care setting. J Med Ethics 2004;30:151-4.
9. Culpepper L, Gilbert TT. Evidence and ethics. Lancet 1999;353:829-31. (Pubitemid 29110419)
10. Vineis P. Evidence-based medicine and ethics: a practical approach. J Med Ethics 2004;30:126-30. (Pubitemid 38559857)
11. Schwartz PH, Meslin EM. The ethics of information: absolute risk reduction and patient understanding of screening. J Gen Intern Med 2008;23:867-70.
12. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med 2010;152:726-32.
13. Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. PLoS Med 2007;4:e297.
14. Mechanic D. Disadvantage, inequality, and social policy. Health Aff 2002;21(2):48-59.
15. Mechanic D. Population health: challenges for science and society. Milbank Q 2007;85:533-59.
16. Oliver A, Healey A, Grand JL. Addressing health inequalities. Lancet 2002;360:565-7. (Pubitemid 35232114)
17. Mackenbach JP, Kunst AE. Measuring the magnitude of socio-economic inequalities in health: an overview of available measures illustrated with two examples from Europe. Soc Sci Med 1997;44:757-71. (Pubitemid 27117431)
18. Harper S, Lynch J. Methods for measuring cancer disparities: a review using data relevant to Healthy People 2010 cancer-related objectives. National Cancer Institute, 2005.
19. Kelly MP, Morgan A, Bonnefoy J, Butt J, Bergmann V. The social determinants of health: developing an evidence base for action. World Health Organization Commission on Social Determinants of Health, 2007.
20. Schwartz LM, Woloshin S, Dvorin EL, Welch HG. Ratio measures in leading medical journals: structured review of accessibility of underlying absolute risks. BMJ 2006;333:1248-50. (Pubitemid 46032354)
21. Harper S, Lynch J, Meersman SC, Breen N, Davis WW, Reichman ME. An overview of methods for monitoring social disparities in cancer with an example using trends in lung cancer incidence by area-socioeconomic position and race-ethnicity, 1992-2004. Am J Epidemiol 2008;167:889-99. (Pubitemid 351521743)
22. Low A, Low A. Measuring the gap: quantifying and comparing local health inequalities. J Public Health 2004;26:388-95. (Pubitemid 40070459)
23. Low A, Low A. Importance of relative measures in policy on health inequalities. BMJ 2006;332:967-9. (Pubitemid 44365559)
24. Regidor E, Sánchez E, de La Fuente L, Luquero FJ, de Mateo S, DomÌnguez V. Major reduction in AIDS-mortality inequalities after HAART: the importance of absolute differences in evaluating interventions. Soc Sci Med 2009;68:419-26.
25. Cornfield J, Haenszel W, Hammond EC, Lilienfeld AM, Shimkin MB, Wynder EL. Smoking and lung cancer: recent evidence and a discussion of some questions. J Natl Cancer Inst 1959;22:173-203.
26. Poole C. On the origin of risk relativism. Epidemiology 2009;21:3-9.
27. Moser K, Frost C, Leon DA. Comparing health inequalities across time and place - rate ratios and rate differences lead to different conclusions: analysis of cross-sectional data from 22 countries 1991-2001. Int J Epidemiol 2007;36:1285-91. (Pubitemid 350238996)
28. Houweling TA, Kunst AE, Huisman M, Mackenbach JP. Using relative and absolute measures for monitoring health inequalities: experiences from cross-national analyses on maternal and child health. Int J Equity Health 2007;6(1):15.
29. Keppel KG. Ten largest racial and ethnic health disparities in the United States based on Healthy People 2010 objectives. Am J Epidemiol 2007;166:97-103. (Pubitemid 47234291)
30. Deaton A. Policy implications of the gradient of health and wealth. Health Aff 2002;21(2):13-30.
31. Mackenbach JP, Kunst AE, Cavelaars AE, Groenhof F, Geurts JJ. Socioeconomic inequalities in morbidity and mortality in western Europe. Lancet 1997;349:1655-9. (Pubitemid 27234807)
32. Vågerö D, Erikson R. Socioeconomic inequalities in morbidity and mortality in western Europe. Lancet 1997;350:516.
33. Levine RS, Briggs NC, Kilbourne BS, King WD, Fry-Johnson Y, Baltrus PT, et al. Black-white mortality from HIV in the United States before and after introduction of highly active antiretroviral therapy in 1996. Am J Public Health 2007;97:1884-92. (Pubitemid 351182302)
34. Borrell C, Rodríguez-Sanz M, Pasarín MI, Brugal MT, García-de-Olalla P, Marí-Dell'Olmo M, et al. AIDS mortality before and after the introduction of highly active antiretroviral therapy: does it vary with socioeconomic group in a country with a national health system? Eur J Public Health 2006;16:601-8. (Pubitemid 44899961)
35. Harper S, Lynch J. Highly active antiretroviral therapy and socioeconomic inequalities in AIDS mortality in Spain. Eur J Public Health 2007;17:231. (Pubitemid 46536740)
36. King NB, Kaufman JS, Harper S. Relative measures alone tell only part of the story. Am J Public Health 2010;100:2014-5.
37. Harper S, King NB, Meersman SC, Reichman ME, Breen N, Lynch J. Implicit value judgments in the measurement of health inequalities. Milbank Q 2010;88:4-29.
38. King NB, Harper SAM, Meersman SC, Reichman ME, Breen N, Lynch J. We'll take the red pill: a reply to Asada. Milbank Q 2010;88:623-7.
39. Braveman P, Egerter S, Williams DR. The social determinants of health: coming of age. Annu Rev Public Health 2011;32:381-98.